A Safety and Efficacy Study of NicaPlant® in Aneurysmal Subarachnoid Haemorrhage Patients Undergoing Aneurysm Clipping

Overview

This study of NicaPlant® is conducted in patients who have a subarachnoid haemorrhage. Patients will be randomized in two treatment groups. Both groups will receive the standard of care and the investigational group will receive in addition NicaPlant®. NicaPlant® is tested to reduce the long-term complications of aneurysmal subarachnoid haemorrhage (aSAH).

Full Title of Study: “A Phase IIb: Randomised, Single-Blind, Safety, Tolerability, Efficacy and Pharmacokinetic Study of NicaPlant® in Aneurysmal Subarachnoid Haemorrhage Patients Undergoing Aneurysm Clipping”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Outcomes Assessor)
  • Study Primary Completion Date: February 2021

Detailed Description

This is a safety, tolerability, efficacy and pharmacokinetic study of NicaPlant® in subarachnoid haemorrhage patients involving two treatment groups. Both treatment groups will receive standard of care and patients randomised to the investigational group will receive in addition NicaPlant® .

NicaPlant® is a nicardipine modified-release formulation. It is presented in the form of a rod-shaped implant with a 4 mg nicardipine load. Following aneurysm clip ligation, 10 NicaPlant® implants will be placed into the basal cisterns in direct contact with the exposed cerebral blood vessel walls.

Interventions

  • Drug: Nicardipine
    • 10 NicaPlant® implants releasing 4 mg nicardipine each.
  • Other: Standard of care
    • Both arms receive the usual standard of care.

Arms, Groups and Cohorts

  • Experimental: NicaPlant®
    • 10 NicaPlant® implants (total 40 mg nicardipine) will be placed after clip ligation into the basal cisterns in direct contact with the exposed cerebral blood vessel walls. In addition patients will receive standard of care for aneurysmal subarachnoid haemorrhage patients according to the treatment guidelines.
  • Other: Control
    • Standard of care for aneurysmal subarachnoid haemorrhage patients according to the treatment guidelines.

Clinical Trial Outcome Measures

Primary Measures

  • Incidence of moderate to severe cerebral angiographic vasospasm assessed by digital subtraction angiography
    • Time Frame: day 8 ± 1 after aneurysm rupture
    • Fishers Exact test
  • Safety by adverse event recording
    • Time Frame: trough study completion, an average of 2 years
    • Descriptive summary

Secondary Measures

  • Incidence of new cerebral infarcts on computer tomography (CT) of the brain versus post-intervention CT scan
    • Time Frame: up to day 14 ± 1 after aneurysm rupture
    • Fishers exact test

Participating in This Clinical Trial

Inclusion Criteria

  • Informed consent obtained according to the Country regulation.
  • Male or female patients aged 18 to 75 years (inclusive).
  • World Federation of Neurological Surgeons (WFNS) grade III-IV.
  • Ruptured saccular aneurysm, confirmed by angiography.
  • Onset of aSAH clinical symptoms within the preceding 48 hours.
  • Treatment of aneurysm via surgical clip ligation within 72 hours of aSAH is achievable.
  • Female patients of child-bearing potential must have a negative pregnancy test (urine or serum) at screening and must agree to use adequate birth control up to 12 weeks after implantation of the study drug. Female patients are considered to be not of child-bearing potential if they have a history of tubal ligation or hysterectomy or are post-menopausal with a minimum of 2 years without a natural menstrual cycle. Male patients must agree to use adequate birth control up to 12 weeks after implantation of the study drug.

Exclusion Criteria

  • SAH due to other causes (e.g. trauma, fusiform or mycotic aneurysm).
  • World Federation of Neurosurgery (WFNS) grade I, II and V patients.
  • Pregnant or Lactating Women.
  • Intraventricular or intracerebral blood, in the absence of subarachnoid blood.
  • Treatment of aneurysm via endovascular embolisation.
  • Presence of moderate or severe vasospasm on screening angiography.
  • Any known or CT /MRI evidence of previous major cerebral damage
  • Evidence of a cerebral infarction with neurological deficit on pre-treatment CT/MRI.
  • History of malignant disease (except for non-melanoma skin cancer) within the previous 5 years or any history of malignant brain tumours or brain metastasis.
  • Patients who have received an investigational product or participated in another interventional clinical study within 30 days prior to randomisation.
  • Patients with known allergy for Poly(D,L-lactide-co-glycolide) (PLGA) or nicardipine.
  • Major complication during aneurysm repair such as, but not limited to, massive intraoperative haemorrhage, brain swelling, or inability to secure the ruptured aneurysm.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • BIT Pharma GmbH
  • Collaborator
    • NeuroScios GmbH
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Claudius Thomé, Prof.Dr., Principal Investigator, Universitätsklinik Innsbruck, Universitätsklinik für Neurochirurgie
  • Overall Contact(s)
    • Tiziana Adage, Dr., +43 (0)664 3972384, tiziana.adage@bit-pharma.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.